| Symbol
| NR2F2
| contributors: mct/npt - updated : 28-11-2023
|
| HGNC name
| nuclear receptor subfamily 2, group F, member 2
|
| HGNC id
| 7976
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --low
|
| |
significantly impaired adult neoangiogenesis (Qin 2010) | | tumoral
|
|
|
| gain of function
|
upregulated in metastatic prostate cancer, and its higher expression correlated with a worse clinical outcome  | | constitutional
|
|
|
| loss of function
| |
mutation is responsible for congenital bicuspid aortic valve | |
| Susceptibility
|
to nonsyndromic atrioventricular septal defects (AVSDs) |
| Variant & Polymorphism
other
| variants in NR2F2 probably contribute to AVSDs and other CHDs during human development |
| 
|
| Candidate gene
| for heart defects in del 15q patients |
|
for isolated congenital diaphragmatic hernia |
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | | | |
| inhibition of NR2F2 may offer a therapeutic approach for anticancer intervention | | cancer | metastases | | |
| . inhibition of NR2F2 suppresses metastases of mammary tumors to the lung | | cancer | reproductive | prostate | |
| is a potential drug target for the intervention of metastatic human prostate cancer |
| | |
|
| decreased dosage of Nr2f2 in mice has been shown to result in abnormal development of atrioventricular septa | |
mice lacking Coup-tf2 die around E10 due to defects of angiogenesis and heart development |